| |
| |
| |
| |
| | | |
|
PR:000000095 | tumor necrosis factor ligand superfamily member 6 | | | | | |
| | | | |
|
PR:000000276 | tumor necrosis factor ligand superfamily member 6 isoform FasL | | | | | |
| | | | | |
|
PR:P48023-1 | tumor necrosis factor ligand superfamily member 6 isoform FasL (human) | | | | | |
| | | | | | |
|
PR:000036458 | tumor necrosis factor ligand superfamily member 6 isoform FasL N-glycosylated 1 (human) | | | | | |
| | | | | | |
|
PR:000036782 | tumor necrosis factor ligand superfamily member 6 isoform FasL sequence variant F273L (human) | | | | | |
| | | | | | |
|
PR:000036459 | tumor necrosis factor ligand superfamily member 6 isoform FasL soluble form (human) | | | | | |
| | | | |
|
PR:P48023 | tumor necrosis factor ligand superfamily member 6 (human) | | | | | |
| | | | | |
|
PR:P48023-1 | tumor necrosis factor ligand superfamily member 6 isoform FasL (human) | | | | | |
| | | | | | |
|
PR:000036458 | tumor necrosis factor ligand superfamily member 6 isoform FasL N-glycosylated 1 (human) | | | | | |
| | | | | | |
|
PR:000036782 | tumor necrosis factor ligand superfamily member 6 isoform FasL sequence variant F273L (human) | | | | | |
| | | | | | |
|
PR:000036459 | tumor necrosis factor ligand superfamily member 6 isoform FasL soluble form (human) | | | | | |
| |
| |
| | | | |
|
PR:P48023 | tumor necrosis factor ligand superfamily member 6 (human) | | | | | |
| | | | | |
|
PR:P48023-1 | tumor necrosis factor ligand superfamily member 6 isoform FasL (human) | | | | | |
| | | | | | |
|
PR:000036458 | tumor necrosis factor ligand superfamily member 6 isoform FasL N-glycosylated 1 (human) | | | | | |
| | | | | | |
|
PR:000036782 | tumor necrosis factor ligand superfamily member 6 isoform FasL sequence variant F273L (human) | | | | | |
| | | | | | |
|
PR:000036459 | tumor necrosis factor ligand superfamily member 6 isoform FasL soluble form (human) | | | | | |